Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Celldex Therapeutics, Inc. (CLDX) had Consolidated Net Income/Loss of $-53.80M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.69M |
|
$-53.80M |
|
-- |
|
$0.69M |
|
$63.43M |
|
$-62.74M |
|
$8.94M |
|
$-53.80M |
|
$-53.80M |
|
$-53.80M |
|
$-53.80M |
|
|
Consolidated Net Income/Loss |
$-53.80M |
$-53.80M |
|
$-62.74M |
|
$-64.14M |
|
66.38M |
|
66.38M |
|
$-0.81 |
|
$-0.81 |
|
| Balance Sheet Financials | |
$693.76M |
|
$4.60M |
|
$45.71M |
|
$739.47M |
|
$32.02M |
|
-- |
|
$4.47M |
|
$36.49M |
|
$702.98M |
|
$675.79M |
|
$702.98M |
|
66.38M |
|
| Cash Flow Statement Financials | |
$-54.37M |
|
$42.95M |
|
$0.20M |
|
$28.36M |
|
$17.14M |
|
$-11.22M |
|
$9.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.67 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-9027.19% |
|
-9027.19% |
|
-- |
|
-7740.43% |
|
-7740.43% |
|
$-54.64M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.65 |
|
137.78 |
|
-7.65% |
|
-7.96% |
|
-7.27% |
|
-7.65% |
|
$10.59 |
|
$-0.82 |
|
$-0.82 |
|